Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone quality in osteogenesis imperfecta].

Hiroyuki Tanaka1

  • 1Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmacology.

Clinical Calcium
|June 3, 2005
PubMed
Summary

Osteogenesis imperfecta (OI) causes brittle bones due to collagen defects. Bisphosphonate treatment may improve bone fragility by increasing bone mass and reducing turnover.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determination of iriflophenone 3-C-β-d-glucoside from Aquilaria spp. by an indirect competitive enzyme-linked immunosorbent assay using a specific polyclonal antibody.

Journal of food science·2013
Same author

A case of cancer of the ampulla of Vater accompanied by malrotation.

The Kurume medical journal·2013
Same author

MLL2 and KDM6A mutations in patients with Kabuki syndrome.

American journal of medical genetics. Part A·2013
Same author

Toll-like receptor 4 mediates retinal ischemia/reperfusion injury through nuclear factor-κB and spleen tyrosine kinase activation.

Investigative ophthalmology & visual science·2013
Same author

Study of 1,3,5-triazine-based catalytic amide-forming reactions: effect of solvents and basicity of reactants.

Chemical & pharmaceutical bulletin·2013
Same author

Treatment of the chronic itch of atopic dermatitis using standard drugs and kampo medicines.

Biological & pharmaceutical bulletin·2013

Area of Science:

  • Genetics and Molecular Biology
  • Orthopedics
  • Pharmacology

Context:

  • Osteogenesis imperfecta (OI) is a group of rare, inherited disorders characterized by bone fragility and low bone mass.
  • Mutations in genes encoding type I collagen (COL1A1, COL1A2) are the primary cause of OI, leading to reduced quantity or quality of collagen.
  • Current treatments aim to manage symptoms, with bisphosphonates showing promise in improving bone health.

Purpose:

  • To explore the underlying genetic causes of Osteogenesis imperfecta.
  • To investigate the mechanism by which bisphosphonate treatment impacts bone fragility in OI patients.
  • To elucidate the relationship between bone turnover, bone mass, and therapeutic outcomes in OI.

Summary:

  • Osteogenesis imperfecta results from genetic mutations affecting type I collagen synthesis or structure, leading to compromised bone integrity.
  • Bisphosphonate therapy demonstrates efficacy in enhancing bone fragility in OI.
  • The therapeutic benefit of bisphosphonates is hypothesized to stem from their ability to inhibit elevated bone turnover, thereby improving bone mass.

Impact:

  • Provides insights into the genetic etiology of Osteogenesis imperfecta, aiding in diagnosis and genetic counseling.
  • Highlights the potential of bisphosphonate therapy as a treatment strategy for improving bone density and reducing fracture risk in OI.
  • Advances understanding of bone remodeling dynamics in heritable bone disorders, informing future therapeutic development.

Related Experiment Videos